Silexion Therapeutics Corp — Form 8-K

Silexion Therapeutics, a KRAS-cancer RNAi therapy developer, reported year-end 2025 cash of $5.991M against total assets of $7.215M and accumulated deficit of $55.166M. The company burned $10.819M in operating cash during 2025, incurred net losses of $11.912M, and management states current funds will cover operations for 'only several months.' As of March 31, 2026 (Q1), cash had fallen to $2.413M, with Q1 2026 net loss of $2.733M; the company raised ~$1.085M under its ATM facility in April-May 2026 post-period. The auditor issued a going-concern warning. The Related Party Promissory Note ($1.633M outstanding at year-end; due Feb 2027) remains a material liability. Three reverse splits (1-for-9, 1-for-15, 1-for-10) occurred in 2024–2026.